This is an interview with Uri Lee, CEO of Xcell Therapeutics. Xcell is an international leader in serum-free, chemically defined media. In this interview, we discuss the mission and purpose of Xcell Therapeutics, its product development pipeline, its rapid growth, and the company’s future goals. Enjoy. [Read more…]
ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 for Rare Diseases and Cancer
RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate via a scalable cGMP manufacturing process in bioreactors, downstream purification, and analytical characterization.
Seoul, South Korea and Frederick, MD, April 26, 2022 – ShiftBio, a leader in the development of innovative exosome platform technologies, announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. This partnership will accelerate ShiftBio’s therapeutic candidates, starting with SBI-102 (Stem cell-derived exosomes expressing a therapeutic ligand), into the clinic. [Read more…]
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 21, 2022 – Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug (IND) indication to date.
[Read more…]
Organicell Regenerative Medicine: Advances of Exosome-Based Therapeutics in the Clinic
Author: Greta Gohring (Research Assistant, Organicell Regenerative Medicine)
Regenerative Medicine is a rapidly expanding sector of biotechnology with numerous innovative therapeutics. Regenerative medicine encompasses a multitude of specialties such as orthopedics, immunology, and cardiology, while following common trends within the fields of tissue and cell engineering. In contrast to common symptom-targeting therapeutics, which temporarily relieve and subdue conditions, regenerative medicine is designed to reprogram damaged or diseased tissues back to a healthy state. Through reprogramming, regenerative medicine has the potential to provide long-term effects in chronic and reoccurring symptomatic diseases. [Read more…]
Exosomes: Company Spotlights from “A” to “Z”
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.
With at least 22,143 scientific articles published about exosomes and 253 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]
- 1
- 2
- 3
- …
- 18
- Next Page »
